AgomAb Therapeutics (NASDAQ:AGMB) Sees Large Volume Increase – Should You Buy?

AgomAb Therapeutics NV (NASDAQ:AGMB) shares saw strong trading volume on Thursday . 179,998 shares were traded during mid-day trading, an increase of 37% from the previous session’s volume of 131,503 shares.The stock last traded at $14.1140 and had previously closed at $13.66.

Analyst Ratings Changes

Several research firms have recently weighed in on AGMB. Piper Sandler assumed coverage on shares of AgomAb Therapeutics in a report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 target price for the company. B. Riley Financial began coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target on the stock. Cantor Fitzgerald began coverage on shares of AgomAb Therapeutics in a report on Wednesday, August 19th. They issued an “overweight” rating for the company. HC Wainwright started coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $35.00 target price on the stock. Finally, Wall Street Zen cut AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.50.

AgomAb Therapeutics Stock Performance

The business has a 50-day moving average price of $13.35 and a 200-day moving average price of $12.51.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. As a group, analysts expect that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.